Chemotherapy for Poor Risk Germ Cell Tumours An Independent Evaluation of the POM B/ACE Regime

Cullen, Michael; Harper, Peter; Woodroffe, C.M.; Kirkbride, Peter; Clarke, Julie

doi:10.1111/j.1464-410x.1988.tb04396.x

Cited by 24 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toxicity was comparable to that published for BEP. Other centres have also had experience with POMB/ACE (Cullen et al, 1988;Husband and Green, 1992), but its advantage over standard BEP has never been tested in a randomised trial. BOMP/EPI is a modification of POMB/ACE, in which POMB is alternated with a modified VIP regimen.…”

Section: Discussionmentioning

confidence: 99%

Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours

Anthoney

McKean

Roberts³

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

Patients with poor and intermediate prognosis metastatic germ-cell tumours (MGCTs) are at a significant risk of relapse after standard platinum-based chemotherapy. Novel treatment regimens are required to improve survival. Dose intense, alternating combinations of drugs with known activity in germ-cell tumours represents one approach. In all, 43 patients with IGCCCG intermediate/poor prognosis MGCT were treated with a dose intense regimen alternating bleomycin, vincristine, cisplatin (BOP) with bleomycin, etoposide, cisplatin (BEP) to a maximum of three cycles. Data were collected on the maintenance of dose intensity, toxicity, response, progression-free (PFS) and overall survival (OS). The complete response rate was 58%; a further 7% of patients being rendered disease free by resection of viable residual tumour. With a median follow-up of more than 4 years in surviving patients, 3-year OS and PFS rates of 81% (95% CI: 66 -91%) and 72% (95% CI: 56 -83%) are seen, respectively. Bleomycin, vincristine, cisplatin (BOP)/bleomycin, etoposide, cisplatin (BEP) was well tolerated, with 86% of patients completing all planned courses. Toxicity was predominantly haematological with common toxicity criteria grade III neutropenia in 90% of patients. Cisplatin neuropathy and bleomycin-induced pulmonary toxicity represented the most significant nonhaematological toxicity. Bleomycin, vincristine, cisplatin (BOP)/bleomycin, etoposide, cisplatin (BEP) represents a practicable, well-tolerated, dose intense chemotherapy regimen with significant activity in intermediate and poor prognosis MGCT.

show abstract

Section: Discussionmentioning

confidence: 99%

Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours

Anthoney

McKean

Roberts³

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Drug combinations in sequence have been explored at the Charing Cross Hospital with cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, and etoposide (POMB/ACE) chemotherapy [16,17]. In 106 patients with large volume metastatic disease (according to the Royal Marsden Hospital staging classification), overall survival was almost 80%.…”

Section: Alternating and Accelerated Chemotherapymentioning

confidence: 99%

Treatment of disseminated non-seminomatous testicular cancer: The European experience

Wit

1999

Sem. Surg. Onc.

View full text Add to dashboard Cite

The majority of patients with disseminated germ cell cancer can be cured with cisplatin‐based combination chemotherapy. For more than a decade the gold standard regimen is cisplatin, etoposide, and bleomycin (BEP). On both sides of the Atlantic, a number of studies have been carried out to either modify the toxicity of therapy in good prognosis patients or to improve the treatment outcome by intensifying the regimen or incorporating new agents in patients with intermediate or poor prognosis disease. This review discusses the trials that have been conducted in Europe, mainly through the European Organization of Research and Treatment of Cancer (EORTC) and Medical Research Council (MRC) in the United Kingdom, as well as the studies that are currently being conducted by the collaborative groups in Europe. Semin. Surg. Oncol. 17:250–256, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

“…Chemotherapy with three cycles of the BEP regimen is recommended for stage IIC and low-risk stage III disease, while four cycles of BEP are considered the standard of care in the intermediaterisk group of patients. However, treatment failures occur in 30% of these cases and may require either surgical resection of residual or new masses or administration of salvage chemotherapy regimens (Miller et al 1997;Motzer et al 1993Motzer et al , 1994Cullen et al 1988;Puc et al 1996). Therefore, a more eVective therapy is required for patients in the intermediate-risk group according to the IGCCCG classiWcation.…”

Section: Introductionmentioning

confidence: 99%

Cisplatin-based chemotherapy for advanced seminoma: report of 52 cases treated in two institutions

Giannis

Bamias

Koutsoukou

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Chemotherapy for Poor Risk Germ Cell Tumours An Independent Evaluation of the POM B/ACE Regime

Cited by 24 publications

References 10 publications

Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours

Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours

Treatment of disseminated non-seminomatous testicular cancer: The European experience

Cisplatin-based chemotherapy for advanced seminoma: report of 52 cases treated in two institutions

Contact Info

Product

Resources

About